Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier

The Journal of Pharmacology and Experimental Therapeutics
Edna F ChooG R Wilkinson

Abstract

A major functional component of the blood-brain barrier is P-glycoprotein. In principle, inhibition of this efflux transporter would permit greater distribution of its substrates into the brain and increased central effects. Tariquidar and elacridar, potent and selective P-glycoprotein inhibitors, were investigated in this regard using the opioid loperamide as an in vivo probe in mice. Pretreatment with both inhibitors converted intravenous loperamide from a drug without central effects to one producing antinociception. Radiolabeled loperamide tissue distribution studies indicated that inhibition was associated with increased uptake into brain and testes in the absence of changes in plasma levels, along with enhanced efflux of rhodamine 123 from CD3e+ T-lymphocytes. However, with tariquidar, the loperamide dose-response curves for testes/plasma and brain/plasma concentration ratios were shifted 6- (p = 0.07) and 25-fold (p < 0.01) to the right, respectively (ED50 = 1.48 and 5.65 mg/kg), compared with the rhodamine 123 efflux curve (ED50 0.25 mg/kg). Less pronounced shifts were noted with elacridar where the brain/plasma ratio was shifted only 2-fold relative to the rhodamine 123 efflux data (ED50 = 2.36 versus 1.34 mg/kg, respe...Continue Reading

References

Oct 9, 1995·International Journal of Cancer. Journal International Du Cancer·A D Didier, F Loor
Feb 7, 1998·The Journal of Clinical Investigation·R B KimG R Wilkinson
May 20, 1999·Annual Review of Pharmacology and Toxicology·S V AmbudkarM M Gottesman
Oct 8, 1999·British Journal of Pharmacology·C MartinR Callaghan
Oct 19, 1999·Molecular and Cellular Biology·E J SmartM P Lisanti
Aug 23, 2000·Molecular Pharmacology·C MartinR Callaghan
Feb 28, 2002·The Journal of Pharmacology and Experimental Therapeutics·Carolyn L CumminsLeslie Z Benet
Nov 15, 2002·Cancer Biology & Therapy·Wafik S El-Deiry
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kelly M Mahar DoanJoseph W Polli
Apr 25, 2003·Cancer Control : Journal of the Moffitt Cancer Center·Hilary Thomas, Helen M Coley
Oct 10, 2003·The Journal of Pharmacology and Experimental Therapeutics·Thomas LitmanWilfred D Stein
Dec 31, 2003·Biochemical Pharmacology·Claude DagenaisGary M Pollack
Jan 7, 2004·Drug Metabolism Reviews·Jiunn H Lin, Masayo Yamazaki
Mar 23, 2004·Biochemical and Biophysical Research Communications·Joachim TroostJohanna Weiss
Apr 23, 2004·Pharmacogenomics·Catia MarzoliniRichard B Kim
Apr 28, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E M KemperO van Tellingen
Sep 15, 2004·European Journal of Clinical Pharmacology·Kyoung-Ah KimJi-Young Park

❮ Previous
Next ❯

Citations

Jul 27, 2007·Naunyn-Schmiedeberg's Archives of Pharmacology·Caroline Henrike StorchJohanna Weiss
Apr 3, 2010·Annals of Nuclear Medicine·Kazunori KawamuraMing-Rong Zhang
May 15, 2008·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Srinivasan SenthilkumariSupriyo Ghose
Mar 11, 2010·Pharmacogenetics and Genomics·Laura M HodgesRuss B Altman
Jul 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jens P BankstahlOliver Langer
Dec 19, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jeih-San LiowRobert B Innis
Nov 17, 2009·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Claudia C WagnerOliver Langer
Feb 20, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Reatul KarimGeraldine Piel
Mar 25, 2015·Expert Opinion on Drug Metabolism & Toxicology·Anna Klukovits, Peter Krajcsi
Oct 2, 2012·European Journal of Pharmacology·Rakesh KumarSubrata Basu Ray
May 9, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Rita Nieto MontesinosAlf Lamprecht
May 1, 2015·The Journal of Membrane Biology·Zsolt FeketePeter Krajcsi
Jun 22, 2012·Journal of Neurochemistry·Gwen McCaffreyThomas P Davis
Feb 12, 2015·Clinical Pharmacology and Therapeutics·R M RaaphorstG Luurtsema
Mar 21, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·O van TellingenH E de Vries
Jul 14, 2009·Journal of Experimental & Clinical Cancer Research : CR·Erin R GardnerAlex Sparreboom
Jun 17, 2016·Expert Review of Neurotherapeutics·Antonin DréanAhmed Idbaih
Apr 13, 2007·Expert Review of Anticancer Therapy·Elizabeth Fox, Susan E Bates
Jan 9, 2014·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Rita Nieto MontesinosYann Pellequer
Oct 18, 2006·The Journal of Pharmacology and Experimental Therapeutics·Steffen BaltesWolfgang Löscher
Jul 8, 2010·The Journal of Pharmacy and Pharmacology·Joris VandenbosschePaul Soons
May 30, 2019·The AAPS Journal·Jean-Marie Nicolas, Elizabeth C M de Lange
Jul 25, 2009·Clinical Pharmacology and Therapeutics·P KannanM D Hall
Feb 3, 2021·International Journal of Molecular Sciences·Justine ParisGuilhem Bousquet
Dec 17, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·William C KreislRobert B Innis
Mar 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Sami S ZoghbiRobert B Innis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.